Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN-AML: Geriatric Assessment-Guided Treatment in Older Adults With AML
NCT07735208Phase 2Not yet recruiting
- Sponsor
- University of Rochester
- Start
- Dec 2026
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by University of Rochester. Primary endpoint: Treatment failure rate at 3 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07735208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735208.